Envestnet Asset Management Inc. Acquires 6,659 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Envestnet Asset Management Inc. lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 124,186 shares of the medical equipment provider’s stock after purchasing an additional 6,659 shares during the quarter. Envestnet Asset Management Inc. owned 0.18% of Lantheus worth $12,121,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Concurrent Investment Advisors LLC acquired a new position in shares of Lantheus in the first quarter valued at approximately $350,000. Moody Aldrich Partners LLC boosted its stake in Lantheus by 0.6% in the 1st quarter. Moody Aldrich Partners LLC now owns 36,205 shares of the medical equipment provider’s stock valued at $3,534,000 after purchasing an additional 217 shares during the period. Principal Financial Group Inc. grew its holdings in Lantheus by 40.2% in the 1st quarter. Principal Financial Group Inc. now owns 258,495 shares of the medical equipment provider’s stock valued at $25,229,000 after buying an additional 74,149 shares in the last quarter. Teacher Retirement System of Texas increased its position in Lantheus by 8.3% during the 1st quarter. Teacher Retirement System of Texas now owns 24,452 shares of the medical equipment provider’s stock worth $2,387,000 after buying an additional 1,884 shares during the period. Finally, Keybank National Association OH lifted its holdings in shares of Lantheus by 87.5% during the first quarter. Keybank National Association OH now owns 576,835 shares of the medical equipment provider’s stock worth $56,299,000 after buying an additional 269,146 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director directly owned 318,650 shares of the company’s stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

LNTH has been the topic of several recent analyst reports. Truist Financial decreased their target price on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. William Blair restated a “market perform” rating on shares of Lantheus in a research report on Wednesday. Wall Street Zen upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Finally, B. Riley decreased their price target on Lantheus from $122.00 to $109.00 and set a “buy” rating on the stock in a research note on Monday, June 23rd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $131.20.

Lantheus Trading Down 4.6%

NASDAQ:LNTH opened at $70.18 on Friday. Lantheus Holdings, Inc. has a one year low of $69.12 and a one year high of $118.21. The company has a market cap of $4.86 billion, a PE ratio of 19.94 and a beta of 0.12. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. The firm has a 50-day moving average of $78.80 and a 200-day moving average of $89.44.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business’s revenue was up .8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.69 EPS. As a group, equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.